Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the ...
Abpro Statement on the Departure of Former CEO Ian Chan
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...
Rhumbline Advisers Grows Stock Holdings in Zura Bio Limited (NASDAQ:ZURA)
Rhumbline Advisers lifted its holdings in shares of Zura Bio Limited (NASDAQ:ZURA – Free Report) by 37.3% during the 4th quarter, according to its most recent 13F filing with the Securities and ...
SanyouBio Launches 73 Whole-Series Bispecific Reference Antibody Products, Facilitating New Breakthroughs in Bispecific Drug Development
SanyouBio announced today the official launch of 73 whole-series bispecific antibody reference products, covering globally approved and representative clinical-stage bispecific antibody drugs. The ...
Abpro Corporation: Abpro Statement on the Departure of Former CEO Ian Chan
Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening ...
GEN - Genetic Engineering and Biotechnology News14d
Input Determines Output Building a Protein Expression Platform
Integrating best practices in AI, genomics, cell culture, and laboratory techniques together contribute to protein expression success.
Caribou Biosciences, Inc.: Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 ...
Cancer Research20d
Abstract A017: Cysteine-Engineered CAR-T Cells to Counter Antigen Escape in B Cell Lymphoma
Therefore, we generated bifunctional CAR-T cells by cysteine-engineering the clinically approved anti-CD19 single-chain variable fragment (scFv) CAR to overcome CD19 antigen escape. Our data ...